Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Testosteronum prolongatum Jelfa

Overdose Scope

Domain	Official Regulatory Statements
Documented overdose presentations:	Symptoms of acute overdose, or exposure to excessive amounts, can involve signs of excess androgen effect, including priapism (frequent, prolonged erection), polycythemia (excessive red blood cell count), and unusual mood changes such as irritability or aggression.
Physiological systems affected (as stated in label):	Cardiovascular (Major Adverse Cardiovascular Events [MACE], Venous Thromboembolism [VTE]); Hepatic (Hepatic Neoplasms, Peliosis Hepatis); Hematologic (Polycythemia); and the Genitourinary system (Priapism).
Dose-related or exposure-related factors (if applicable):	Serious and life-threatening outcomes, such as liver tumors or MACE, are particularly associated with the prolonged use of high doses or abuse scenarios.
Population-specific overdose notes (if applicable):	In patients with pre-existing cardiac, renal, or hepatic disease, overexposure carries a significant risk of developing or exacerbating edema, which may progress to congestive heart failure. In women, overdose may lead to irreversible virilization.
Emergency-response statements (as written in official documents):	The required management for an overdose is symptomatic and supportive treatment. Discontinuation of the drug is mandated if specific severe adverse events, such as VTE, significant polycythemia, or hypercalcemia, are suspected.
When immediate medical help is required (label-derived phrasing only):	Seek immediate emergency attention for any signs of collapse, seizure, or trouble breathing. Contact a healthcare professional immediately if priapism is frequent or persistent, or if there is new onset or worsening of suicidal ideation or severe mood changes.

Overdose Classifications (High-Level)

Classification Aspect	Official Regulatory Statement
Severity classification (as defined in official documents):	Manifestations range from distinct, reversible symptoms of androgen excess to severe, life-threatening complications associated with high exposure.
Regulatory basis (EMA / FDA / etc.):	Overdose information is defined by major regulatory bodies as concerning the consequences of excessive testosterone levels.
Overdose-context constraints (as defined in official documents):	No specific antidote is known for overdose of testosterone products.

Resulting Overdose Structure

Official overdose statements:

Overdose may present with distinct signs of androgen excess, including priapism and significant, unusual mood changes or aggressiveness.
Severe outcomes associated with high or prolonged exposure include the potential for Major Adverse Cardiovascular Events (MACE) and life-threatening hepatic complications.
The mandated procedure for managing overdose is symptomatic and supportive treatment, with no specific antidote documented.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile primarily through the manifestations of excessive androgen exposure, which necessitates the official requirement to discontinue the drug and institute symptomatic and supportive treatment. The official guidance dictates that emergency medical help must be sought immediately for severe, acute symptoms such as collapse or seizures, and for less acute but damaging signs like persistent priapism, exactly as described in the official label instructions. The absence of a specific antidote means the focus is placed on monitoring and managing the specific documented toxicities.

Therapeutic Uses of Testosteronum prolongatum Jelfa

What Testosteronum prolongatum Jelfa Treats: Main Uses and Benefits

The medication is generally used in clinical settings to address conditions presenting with systemic or localized discomfort associated with a confirmed deficiency in men, a state known as male hypogonadism. Its primary goal is to support patients during episodes of heightened discomfort.

The medication is commonly used to help with managing systemic symptoms in patients with confirmed hypogonadism, including decreased libido and erectile difficulties, reduced muscle bulk and strength, and depressive moods and chronic fatigue. It is applied in scenarios where additional management of discomfort is required and needs foundational supportive relief.

This supportive therapeutic benefit assists with managing symptoms related to systemic imbalance, contributing to improved comfort and stability during symptomatic phases.

The key therapeutic benefit is commonly used to help with managing symptoms related to systemic imbalance, which assists with maintaining functional stability.

Quick Fact: Relief for Symptom Clusters that Interfere with Daily Functioning

Target Condition: Male Hypogonadism (conditions characterized by periods of heightened symptoms)
Goal: Applied in contexts where additional symptomatic support is needed.
Benefit: Contributes to easing the overall symptom load and supports general well-being.

Regulatory References

NIH DailyMed overview

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use This Medicine

The eligibility for Testosteronum prolongatum Jelfa, like other testosterone replacement products, is strictly defined by government regulatory documents, primarily restricting use to adult males (18 years and older) who have a medically confirmed deficiency or absence of endogenous testosterone.

Absolute Contraindications (Must Not Use)

Official labeling mandates that this medicine is contraindicated (must not be used) in several patient populations:

Men with known or suspected carcinoma of the prostate or carcinoma of the breast.
All women, especially those who are pregnant or breastfeeding, due to the risk of fetal harm and adverse effects on nursing infants.
Patients with a known hypersensitivity to the active substance or any excipients.

Restricted or Conditional Use

Use is not established and therefore not recommended for males under 18 years old (pediatric use) or for treating age-related hypogonadism alone. Additionally, patients with pre-existing conditions such as severe cardiac, renal, or hepatic disease must use the medicine with special caution and monitoring due to the risk of fluid retention. Close clinical oversight is also required for geriatric patients and those with Benign Prostatic Hyperplasia (BPH) or risk factors for Polycythemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes the potential interactions of Testosteronum prolongatum Jelfa based on documented regulatory information. It is important to note that testosterone can alter the effects of certain medications, requiring close medical supervision and potentially dose adjustments.

Clinically Significant Interactions

The most significant interactions involve the following classes of medicines:

Insulin and other Anti-diabetic Agents: Testosterone may enhance the blood glucose-lowering effects of these medicines. This interaction can lead to a decrease in blood glucose and a reduction in the required insulin or anti-diabetic agent dose in patients with diabetes. Close monitoring of blood glucose levels is essential.
Oral Anticoagulants: The combination of testosterone with oral anticoagulants (blood thinners) may result in changes in anticoagulant activity. This necessitates frequent monitoring of coagulation parameters, such as the International Normalized Ratio (INR) and prothrombin time, to prevent bleeding complications.
Corticosteroids: Concomitant use with corticosteroids, which are used to treat inflammation and various conditions, can lead to increased fluid retention. Caution is advised, particularly for individuals with pre-existing cardiac, renal, or hepatic disease.
Drugs that may also increase blood pressure: Use with these agents may lead to additional increases in blood pressure, requiring regular monitoring.

Management

Patients must inform their healthcare provider about all medicines they are taking. Dose adjustments for anticoagulants and anti-diabetic agents are commonly required when starting or stopping testosterone therapy to maintain therapeutic control and safety.

Mechanism of Action

Exogenous testosterone, released from the hydrolyzed testosterone ester, binds to the androgen receptor (AR), a nuclear receptor. AR activation modulates the transcription of genes involved in the regulation of bone mineralization, myogenesis, and hypothalamic-pituitary-gonadal axis feedback. The activated AR complex translocates to the nucleus and acts as a transcription factor, increasing gene expression related to protein synthesis and the release of erythropoietic stimulating factors. The mechanism also involves a negative feedback loop where testosterone and its metabolites inhibit the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. Testosterone affects the hypothalamus, reducing the release of Gonadotropin-releasing hormone (GnRH).

Dosage and Administration Information

Instruction Map: How to use Testosteronum prolongatum Jelfa — official administration guidelines

Administration Scope

Route of administration: This medicine is strictly for deep intramuscular (IM) injection into the gluteal muscle.

Dosing schedule: The dose is individualized based on the patient's requirement and monitored hormone levels. Dosing typically ranges from 50 mg to 400 mg per injection, with the overall total dose generally not exceeding 400 mg per month.

Timing in relation to meals (if applicable): Not applicable, as this is an injectable medicine.

Preparation requirements (if applicable): The oily solution must be administered very slowly (in some cases, over two minutes). If crystals are present, the ampoule may be warmed and shaken to re-dissolve them prior to administration.

Age-group administration rules: Children and Adolescents are not indicated for use, as the safety and efficacy of the injection are not adequately determined in this population. Limited data suggest no specific dosage adjustment is necessary for older adults.

Missed-dose rules: The prescribed injection interval may be shortened if measured serum testosterone levels are below the normal range at the end of the dosing cycle, or extended if levels are too high.

Special procedural conditions: Monitoring of total serum testosterone levels must be performed before starting treatment and periodically thereafter; measurements should occur at the end of the injection interval to guide dosage adjustments.

Instruction Classifications (High-Level)

Administration method type (oral / IV / topical / inhaled / etc.): Intramuscular injection.

Frequency pattern (daily / weekly / as-needed, etc.): Intermittent, typically administered every 2 to 6 weeks.

Regulatory basis: Standard medicinal parameters and corresponding national guidelines.

Use-context constraints: Use is contingent upon periodic laboratory monitoring of serum testosterone levels to guide individual dose and frequency adjustments.

Resulting procedural structure

Official step sequence:

Confirm the need for deep intramuscular administration.
Administer the individualized dose (in the 50 mg–400 mg range) at the specific, adjusted interval.
Adjust the subsequent interval or dose based on periodic serum testosterone level monitoring.

Connection to the overall use protocol (2–4 sentences): Official instructions establish that Testosteronum prolongatum Jelfa is a long-term replacement therapy requiring a specialized administration method. The core use protocol is built on the premise that the dosage and frequency (every 2 to 6 weeks) must be entirely dependent on laboratory monitoring of the patient’s hormone levels. This ensures the delivery of an individualized dose within approved parameters.

Recent Clinical Evidence

Research evidence / Overview of Studies for Testosterum prolongatum Jelfa

Evidence for use in Confirmed Male Hypogonadism

Testosteronum prolongatum Jelfa, which contains Testosterone Enanthate, was studied for use in adult men who have a confirmed deficiency in their body’s natural testosterone production—a condition known as hypogonadism. Published research exploring the properties of this formulation included formal Clinical Trials and also utilized Systematic Reviews. These studies primarily focused on two areas: patterns related to hormone levels that the injection system maintains and patterns related to patient-reported symptoms.

Research examined the unique prolonged-action nature of this specific formulation, exploring the achievement and maintenance of hormone levels and how this relates to trials assessing short-term or episodic symptom patterns linked to deficiency. PK/PD studies monitored the stability of hormone concentrations over defined time intervals. These studies often involved observing responses over defined time intervals to describe the drug's sustained action properties.

Measuring Outcomes: Hormone Stability and Symptom Clusters

In addition to monitoring hormone levels, studies were evaluated in men presenting with conditions involving periods of heightened symptoms. Specific outcomes related to systemic or functional imbalance that were observed in these men included the measurement of decreased libido and erectile difficulties. Other outcomes research examined were measures of reduced muscle bulk and strength and the assessment of energy and mood, such as chronic fatigue and depressive moods. The findings describe patterns observed in the studies where specific physical and metabolic measures, like bone density, were evaluated in the observed populations.

What is Still Uncertain About the Research for Testosteronum prolongatum Jelfa

A key area of uncertainty is the extent of limited information for long-term outcomes across all measured symptoms. While some patterns were observed in some studies, certainty remains low regarding the long-term functional outcomes that were observed in some studies.

Furthermore, evidence quality varies across studies, and the findings have sometimes been mixed, particularly when comparing results across different populations and study designs. For certain outcomes, sample sizes were modest in some trials, and follow-up durations were limited. This means that research describes group patterns, not personal outcomes, and the evidence highlights what is known—and what is still uncertain—about the findings related to this medicine in men with hypogonadism.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Testosteronum prolongatum Jelfa (FAQ)

Q: Is there a need to monitor prostate health (e.g., PSA levels) during therapy?

Official product information states that prostate health monitoring is generally required while using this type of medicine, including checking the prostatic specific antigen (PSA) levels periodically. This requirement addresses the possibility that testosterone treatment may worsen pre-existing benign prostatic hyperplasia (BPH) or increase the potential risk related to prostate carcinoma.

Q: How does this medication affect the natural production of testosterone by the body?

The introduction of external testosterone suppresses the body's natural hormone production through a process known as negative feedback. This is a recognized pharmacological action where the increase in external hormone signals the pituitary gland to reduce the release of hormones like LH and FSH, which are necessary for the body to produce its own testosterone.

Q: Why is this medication given as an injection into the muscle rather than under the skin?

Regulatory instructions require this medicine to be given as a deep intramuscular injection because it is a specialized oily solution. This method allows the medicine to form a depot (a small storage area) within the muscle tissue. The depot structure is what enables the testosterone to be slowly released into the body over several weeks, providing the medicine's prolonged action.

Q: How quickly can a person expect to notice any effects after starting treatment?

Studies indicate that the time it takes to notice effects can vary based on the specific symptom being monitored. Improvements in sexual interest may be observed in some patients after approximately three weeks of treatment. Other changes, such as effects on energy or mood, might take longer, potentially becoming noticeable after three to six weeks.

Q: Can this medication potentially worsen symptoms of sleep apnea?

Official warnings indicate that treatment with testosterone products may potentially worsen sleep apnea, which is a condition where breathing repeatedly stops and starts during sleep. The regulatory labeling notes that patients with existing risk factors for sleep apnea may require increased clinical oversight.

Q: What signs or symptoms should prompt a person to seek medical attention immediately?

Official warnings instruct that individuals must contact a healthcare provider immediately if they experience sudden symptoms that may indicate a serious event. These symptoms include sudden swelling or pain in a leg or arm (suggesting a blood clot), slurred speech or sudden weakness on one side of the body (suggesting a stroke), or chest pain and difficulty breathing (suggesting a heart attack).

Q: How does Testosteronum prolongatum Jelfa affect the ability of a male patient to father children (fertility)?

Studies indicate that using external testosterone can temporarily impair male fertility because the medicine suppresses the hormonal axis responsible for producing sperm. Clinical documents suggest that this effect on sperm production is commonly reversed after treatment is discontinued.

Q: Is there a risk of decreased sperm count while undergoing this treatment?

Yes, a known pharmacological effect of testosterone administration is the suppression of spermatogenesis (sperm production). This suppression can compromise the sperm count significantly, and in some cases, may result in azoospermia (the absence of sperm).

Q: What is the chemical difference between testosterone enanthate and testosterone cypionate?

Both testosterone enanthate (the active ingredient in this medicine) and testosterone cypionate are long-acting ester formulations used in replacement therapy. The chemical difference is minor, relating to the length of the attached ester chain. While this causes slight variations in absorption rates, they are often described in clinical literature as similar in overall effect.

Q: What is the half-life of Testosteronum prolongatum Jelfa (testosterone enanthate)?

According to pharmacological data, the half-life of testosterone enanthate is approximately 7 to 10 days. The half-life is the time it takes for the concentration of the medicine in the body to be reduced by half.

How should Testosteronum prolongatum Jelfa be stored and disposed of?

Official Storage and Handling Requirements

Testosteronum prolongatum Jelfa must be stored strictly according to the official regulatory instructions to ensure product stability. The required storage temperature is below 25°C (77°F), and the product must not be frozen.

The medicine should be kept in the original package to provide protection from light. It is mandatory to keep the product out of the sight and reach of children at all times.

Stability and Disposal

The solution for injection must be used immediately after the ampoule is opened. If the oily solution appears cloudy, it can be clarified by warming the ampoule gently in warm water.

Unused or expired Testosteronum prolongatum Jelfa must not be discarded via household waste or wastewater. Patients must consult a pharmacist for instructions on proper pharmaceutical waste disposal.

Property	Description
Active Ingredient	Testosterone Enanthate
Form	Solution for Intramuscular Injection
Pharmacological Class	Androgen (Sex Hormone)
Common Use	Hormone Replacement
Origin	Synthetic Ester (Derived)

Testosteronum prolongatum Jelfa